Aquestive Therapeutics, Inc.
AQST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $309 | $124 | $44 | $148 |
| - Cash | $72 | $24 | $27 | $28 |
| + Debt | $38 | $33 | $57 | $56 |
| Enterprise Value | $275 | $133 | $74 | $177 |
| Revenue | $58 | $51 | $48 | $51 |
| % Growth | 13.8% | 6.1% | -6.2% | – |
| Gross Profit | $40 | $30 | $28 | $36 |
| % Margin | 69% | 58.8% | 59.3% | 70.5% |
| EBITDA | -$27 | $1 | -$40 | -$45 |
| % Margin | -46.2% | 2.3% | -83% | -88.8% |
| Net Income | -$44 | -$8 | -$54 | -$71 |
| % Margin | -76.7% | -15.6% | -114.1% | -138.8% |
| EPS Diluted | -0.51 | -0.13 | -1.12 | -1.85 |
| % Growth | -292.3% | 88.4% | 39.5% | – |
| Operating Cash Flow | -$36 | -$6 | -$10 | -$33 |
| Capital Expenditures | -$0 | -$1 | -$3 | -$1 |
| Free Cash Flow | -$36 | -$7 | -$12 | -$34 |